Abstract:Abstract Background Clostridium difficile (C.Diff) is a gram positive anaerobe producing Enterotoxin and Cytotoxin (toxin A and B respectively); toxin B has been reported to be essential for its virulence. It is estimated that C. Diff will cause over half a million infection yearly and one in 11 people over the age of 65 diagnosed with healthcare-associated C.Diff infection die within one month. It is the most common cause of acute diarrhea; residents in Long-Term Care Facilities (LTCF) are more prone to have C. Diff infection (CDI) because of their age, the frequent use of antibiotics, fragilities, co-morbidity, and living environment. Diagnosing CDI is based on clinical signs and symptoms as well as laboratory tests. Several tests available for diagnosing the infection which include: enzyme immunoassays, tissue culture cytotoxicity, anaerobic culture, glutamate dehydrogenase antigen and nucleic acid amplification. The BD MAXTM System is a PCR based assay that provides the sensitivity, specificity and faster turnaround. Methods The MAXTM System is an automated in vitro diagnostic test for the direct qualitative detection of the C. difficile toxin B gene (tcdB) in human liquid or soft stool specimens from patients suspected of having Clostridium difficile Infection (CDI).The test is performed directly on the specimen, utilizing real-time polymerase chain reaction (PCR) for the amplification of C. difficile toxin B gene (tcdB). The test utilizes fluorogenic sequence-specific hybridization probes for detection of the amplified DNA. The test was validated for accuracy, precision, and patient correlation to enzyme-immunoassay using Premier Toxins A & B is an enzyme immunoassay for the direct detection of Clostridium difficile toxin A and toxin B in stool samples. Statistical analyses were done using Analyse-it. Results The percentage agreement for precision, reproducibility, and accuracy were 100%. We had 100% agreement for positive patients on EIA and 85% for negative patients on EIA; however, upon investigation we found the discrepancies were due to false negative EIA results. Conclusion The BD Max gave the benefit of a fully automated with high sensitivity and specificity for the presence of toxin B producing C. Diff. The faster turnaround gives the physician the ability to diagnose CDI and prevent spreading of the disease to other patients. It is very important to remember that C.diff infection can be prevented with appropriate use of antibiotics and implementing antibiotic stewardship and infection control plan to prevent and stop spreading of the infection.

Comparison of Two Molecular Methods for Detecting Toxigenic Clostridium Difficile.

Detection of Clostridium Difficile As a Routine Diagnosis: Comparison of Real-Time PCR and Enzyme Immunoassay

Assessment Of Clostridium Difficile Infections By Quantitative Detection Of Tcdb Toxin By Use Of A Real-Time Cell Analysis System

Evaluation of a Chromogenic Culture Medium for the Detection Ofclostridium Difficile

Comparison of a Commercial Multiplex Real-Time PCR to the Cell Cytotoxicity Neutralization Assay for Diagnosis of Clostridium Difficile Infections

Clinical evaluation of three methods in detection of Clost ridium difficile in stool

Applicability of Commercial Multiplex Kit for the Diagnosis Of: a Multicenter Investigation Clostridium Difficile Infections

Comparison of the STANDARD M10 C. difficile, Xpert C. difficile, and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing Clostridioides difficile infection

Clinical evaluation of GeneXpert real-time fluorescence quantitation PCR in rapid detection of Clostridium difficile

Molecular Epidemiology and Antimicrobial Susceptibility of Clostridium Difficile Isolated from Hospitals During a 4-Year Period in China.

Rapid discrimination between clinical Clostridioides difficile infection and colonization by quantitative detection of TcdB toxin using a real-time cell analysis system

Comparison of rectal swabs and fecal samples for the detection of Clostridioides difficile infections with a new in-house PCR assay

[Evaluation of the Clinical Validity of the Clostridioides difficile Nucleic Acid Detection Kit "Smart Gene® CD ToxinB"]

Impact of the Reverse Two-Step Algorithm for Clostridioides difficile Testing in the Microbiology Laboratory on Hospitalized Patients

A rapid multiplex real-time PCR detection of toxigenic Clostridioides difficile directly from fecal samples

Advances in diagnostic assays for Clostridioides difficile infection in adults

Diagnostic Guidance for C. difficile Infections

Nationwide Survey for Current Status of Laboratory Diagnosis of Clostridioides difficile Infection in Korea

A-286 Performance Evaluation of Molecular Clostridium Difficile Assay using BD MaxTM System

Detection of Clostridium difficile toxins A and B in inpatient stool samples by enzyme-linked fluorescent immunoassay

Performance of C. DIFF QUICK CHEK COMPLETE